Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Stage of Development | 8 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Therapy Area | 9 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Indication | 10 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Products under Development by Companies | 13 | 2 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Therapeutics Assessment | 15 | 4 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Companies Involved in Therapeutics Development | 19 | 6 |
| Daiichi Sankyo Company, Limited | 19 | 1 |
| Intellipharmaceutics International Inc. | 20 | 1 |
| Mapi Pharma Ltd. | 21 | 1 |
| Pfizer Inc. | 22 | 1 |
| Prismic Pharmaceuticals, Inc. | 23 | 1 |
| Yuhan Corporation | 24 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Drug Profiles | 25 | 15 |
| (palmidrol + pregabalin) Drug Profile | 25 | 1 |
| gabapentin Drug Profile | 26 | 1 |
| mirogabalin besylate Drug Profile | 27 | 2 |
| NVA-1309 Drug Profile | 29 | 1 |
| pregabalin Drug Profile | 30 | 4 |
| pregabalin CR Drug Profile | 34 | 2 |
| pregabalin CR Drug Profile | 36 | 1 |
| pregabalin ER Drug Profile | 37 | 1 |
| pregabalin IR Drug Profile | 38 | 1 |
| pregabalin XR Drug Profile | 39 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Dormant Projects | 40 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Discontinued Products | 41 | 1 |
| Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Featured News &Press Releases | 42 | 9 |
| Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules | 42 | 1 |
| Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain | 42 | 1 |
| Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica | 42 | 1 |
| Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate | 43 | 1 |
| Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia | 43 | 1 |
| Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin | 43 | 1 |
| Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia | 44 | 1 |
| Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective | 45 | 1 |
| Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting | 46 | 1 |
| Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin | 47 | 1 |
| Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release) | 47 | 1 |
| Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China | 48 | 1 |
| Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case | 49 | 1 |
| Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion | 49 | 1 |
| Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |